§
Luxuse
Patent Intelligence
Sign In
Patent US4273775A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4273775A Expired / Lapsed US ⏱️ 0.0 years remaining

Hydantoin derivatives, anti-diabetic compositions thereof, and method of use thereof

Assignee: Pfizer Inc
•
Filing: 1980-05-27
•
Granted: 1981-06-16
•
Expires: 2000-05-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A series of novel tetrahydroquinoline-derived spiro-hydantoin compounds has been prepared, including their pharmaceutically acceptable acid addition salts. These particular compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Preferred member compounds include 1'-methyl-1',2',3',4'-tetrahydro-spiro-[imidazolidine-4,4'-quinoline]- 2,5-dione, 6'-chloro-1',2',3',4'-tetrahydro-spiro-[imidazolidine-4,4'-quinoline]- 2,5-dione, 7'-chloro-1',2',3',4'-tetrahydro-spiro-[imidazolidine-4,4'-quinoline]- 2,5-dione and 1'-methyl-1',2',3',4'-tetrahydro-spiro-[imidazolidine-4,4'-pyrido(2,3- b)pyridine]-2,5-dione. Methods for preparing these compounds from known starting materials are provided.

Inventors

  • 👤 Reinhard Sarges

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 18:25
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/10

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 21 words
A compound of the formula: ##STR3## and the pharmaceutically acceptable acid addition salts thereof, wherein R is hydrogen or lower alkyl.
Claim 2
Dependent Claim 21 words
A compound of the formula: ##STR3## and the pharmaceutically acceptable acid addition salts thereof, wherein R is hydrogen or lower alkyl.
Claim 3
Dependent Claim 16 words
A compound as claimed in claim 1 of the formula II wherein R is lower alkyl.
Claim 4
Dependent Claim 11 words
A compound as claimed in claim 2 wherein R is methyl.
Claim 5
Dependent Claim 1 words
1'-Methyl-1',2',3',4'-tetrahydro-spiro-[imidazolidine-4,4'-pyrido(2,3-b)pyridine]-2,5-dione.
Claim 6
Dependent Claim 1 words
1'-Methyl-1',2',3',4'-tetrahydro-spiro-[imidazolidine-4,4'-pyrido(2,3-b)pyridine]-2,5-dione.
Claim 7
Dependent Claim 38 words
A method for treating a diabetic host to prevent or alleviate ocular or neuritic diabetes-associated chronic complications, which comprises administering to said diabetic host an alleviating or prophylactically effective amount of a compound as claimed in claim 1.
Claim 8
Dependent Claim 33 words
A composition suitable for oral administration comprising a pharmaceutically acceptable carrier and a compound as claimed in claim 1 in an amount effective for the treatment of ocular or neuritic diabetes-associated chronic complications.

References Cited (Backward Citations)

US3821383A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-06-15 1984-12-15 1985-06-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-06-15 1988-12-15 1989-06-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-06-15 1992-12-15 1993-06-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag